Aura Biosciences is a biotech company headquartered in Cambridge, Massachusetts. They are focused on developing tumor-targeted therapies using nanotechnology. Their lead candidate is a viral-like particle conjugated to an infra-red activated small molecule, which selectively binds to and destroys cancer cells in the eye. By leveraging this technology, Aura Biosciences aims to treat ocular melanoma at an early stage, preventing its progression and metastasis to the liver, where it becomes fatal.